Biotech startups that raised Series A in Shanghai, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| SynMetaBio | Shanghai | Series A | $14.7M | 2026-07-06 |
| Degron Therapeutics | Shanghai | Series A | $40.0M | 2026-05-14 |
| Allink Biotherapeutics | Shanghai | Series A | $47.0M | 2025-12-16 |
| Brise Pharma | Shanghai | Series A | $28.1M | 2025-11-11 |
| Positive Sequence Biology | Shanghai | Series A | $13.9M | 2024-08-08 |
| St Phi Therapeutics | Shanghai | Series A | $13.8M | 2024-04-15 |
| Rongcan Bio | Shanghai | Series A | $14.0M | 2023-12-06 |
| Zilixir Biotech | Shanghai | Series A | $14.1M | 2023-05-25 |
8 rows of the CSV in 5 of its 18 columns.
- The 76 biotech startups in Shanghai, China whose last round is Series A have raised $2.1B in total.
- 14 of them closed their most recent round in the last 12 months, $516.8M combined.
- The largest of those rounds is Anew Labs' $290.0M Series A, dated September 2026.
- BioVenture is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 64 companies (84%).
- 49% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 11 to 50 employees (51% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
4 of 76| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
| Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| Brise Pharma | Brise Pharma provides scientific research and technical services in the pharmaceutical field. | Biotech | Series A | $28.1M | 2025-11-11 | $228.3M | Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 | 11 to 50 | 2021 |
Table 1. Biotech startups that raised Series A in Shanghai, China: the 4 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 76.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| 2 | Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| 3 | SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series A in Shanghai, China: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | BioVenture | Venture capital firm | Suzhou, China | 2 | 3% | 2 | Degron Therapeutics, Allink Biotherapeutics |
| 2 | New Alliance Capital | Private equity firm | Shanghai, China | 2 | 3% | 1 | Degron Therapeutics |
| 3 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 3% | ||
| 4 | Panacea Venture | Venture capital firm | Shanghai, China | 2 | 3% | ||
| 5 | MiraclePlus | Startup accelerator | Haidian, China | 1 | 1% | 1 | SynMetaBio |
| 6 | Linear Capital | Venture capital firm | Shanghai, China | 1 | 1% | 1 | SynMetaBio |
| 7 | Danen Capital | Venture capital firm | Shenzhen, China | 1 | 1% | 1 | SynMetaBio |
| 8 | Cowin Venture | Angel group | Beijing, China | 1 | 1% | 1 | Degron Therapeutics |
| 9 | Baidu Ventures | Venture capital firm | Beijing, China | 1 | 1% | 1 | Degron Therapeutics |
| 10 | Med-Fine Capital | Venture capital firm | Shanghai, China | 1 | 1% | 1 | Degron Therapeutics |
| 11 | Gaorong Capital | Venture capital firm | Wangjing, China | 1 | 1% | 1 | Allink Biotherapeutics |
| 12 | Xiamen C&D Emerging Industry Equity Investment | Private equity firm | Xiamen, China | 1 | 1% | 1 | Allink Biotherapeutics |
| 13 | Lanchi Ventures | Venture capital firm | Singapore | 1 | 1% | 1 | Allink Biotherapeutics |
| 14 | Legend Capital | Venture capital firm | Beijing, China | 1 | 1% | 1 | Allink Biotherapeutics |
| 15 | Boyuan Capital | Venture capital firm | Shanghai, China | 1 | 1% |
Table 3. Biotech startups that raised Series A in Shanghai, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 64 | 84% | $1.7B |
| Software | 6 | 8% | $293.0M |
| Artificial intelligence | 4 | 5% | $293.0M |
| Hardware | 2 | 3% |
Table 4. Biotech startups that raised Series A in Shanghai, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 76 | 100% | $20.0M |
Table 5. Biotech startups that raised Series A in Shanghai, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 7% | |
| September 2026 | 1 | 7% | $290.0M |
| August 2026 | 1 | 7% | |
| July 2026 | 2 | 14% | $44.3M |
| May 2026 | 2 | 14% | $76.8M |
| January 2026 | 3 | 21% | $14.4M |
| December 2025 | 4 | 29% | $91.3M |
Table 6. Biotech startups that raised Series A in Shanghai, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 10 | 13% | $425.5M |
| 2025 | 14 | 18% | $410.6M |
| 2024 | 10 | 13% | $61.3M |
| 2023 | 10 | 13% | $56.9M |
| 2022 | 8 | 11% | $214.3M |
| 2021 | 9 | 12% | $88.4M |
Table 7. Biotech startups that raised Series A in Shanghai, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 4% |
| 2020 to 2022 | 33 | 45% |
| 2015 to 2019 | 25 | 34% |
| 2010 to 2014 | 7 | 10% |
| Before 2010 | 5 | 7% |
Table 8. Biotech startups that raised Series A in Shanghai, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 8 | 14% |
| 11 to 50 | 30 | 51% |
| 51 to 100 | 9 | 15% |
| 101 to 250 | 4 | 7% |
| 251 to 500 | 5 | 8% |
| 501 to 1,000 | 1 | 2% |
| 1,001 to 5,000 | 1 | 2% |
| 5,001 to 10,000 | 1 | 2% |
Table 9. Biotech startups that raised Series A in Shanghai, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Shanghai, China. On 16 November 2026 that is 76 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 4 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 76 rows: 30 have no round amount, 0 no city and 19 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Shanghai, China whose last round is Series A are on the list?
- 76, in the file dated 16 November 2026. 14 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 76 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.